Go Pro
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel Free LRMR Stock Alerts

Larimar Therapeutics (LRMR) Financials

Larimar Therapeutics logo
$3.26 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$3.29 +0.03 (+0.80%)
As of 07/2/2026 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Larimar Therapeutics

Annual Income Statements for Larimar Therapeutics

This table shows Larimar Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -74 -58 -52 -61 -23 -42 -51 -35 -37 -81 -166
Consolidated Net Income / (Loss)		 -74 -58 -52 -61 -23 -42 -51 -35 -37 -81 -166
Net Income / (Loss) Continuing Operations		 -74 -58 -52 -61 -23 -42 -51 -35 -37 -81 -166
Total Pre-Tax Income 		-74 -58 -52 -61 -23 -42 -51 -35 -37 -81 -172
Total Operating Income		 -74 -58 -53 -61 -23 -43 -50 -37 -42 -91 -172
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 74 58 53 61 23 43 50 37 42 91 172
Selling, General & Admin Expense		 19 18 12 13 2.42 11 12 12 14 18 18
Research & Development Expense		 55 40 41 48 21 31 38 24 28 73 154
Total Other Income / (Expense), net		 -0.47 0.35 0.97 -0.25 0.08 0.32 -0.17 1.17 4.81 10 0.00
Other Gains / (Losses), net		 - - - - - - - - - - 6.82
Basic Earnings per Share		 ($2.78) ($2.12) ($1.90) ($1.90) ($3.80) ($3.57) ($2.95) ($1.37) ($0.84) ($1.32) ($3.46)
Weighted Average Basic Shares Outstanding		 26.76M 27.30M 27.43M 32.23M 6.09M 11.88M 17.16M 25.76M 43.90M 61.26M 73.20M
Diluted Earnings per Share		 ($2.78) ($2.12) ($1.90) ($1.90) ($3.80) ($3.57) ($2.95) ($1.37) ($0.84) ($1.32) ($3.46)
Weighted Average Diluted Shares Outstanding		 26.76M 27.30M 27.43M 32.23M 6.09M 11.88M 17.16M 25.76M 43.90M 61.26M 73.20M
Weighted Average Basic & Diluted Shares Outstanding		 26.76M 27.30M 27.43M 32.23M 6.09M 11.88M 17.71M 43.27M 63.80M 64.03M 103.88M

Quarterly Income Statements for Larimar Therapeutics

This table shows Larimar Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.06 -13 -15 -22 -15 -29 -29 -26 -48 -62 -30
Consolidated Net Income / (Loss)		 -9.06 -13 -15 -22 -15 -29 -29 -26 -48 -62 -30
Net Income / (Loss) Continuing Operations		 -9.06 -13 -15 -22 -15 -29 -29 -26 -48 -62 -30
Total Pre-Tax Income 		-9.06 -13 -15 -22 -15 -29 -29 -26 -48 -69 -31
Total Operating Income		 -10 -14 -17 -25 -18 -31 -31 -28 -49 -64 -31
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 10 14 17 25 18 31 31 28 49 64 31
Selling, General & Admin Expense		 3.75 3.51 3.80 4.92 4.35 4.56 4.64 4.42 4.57 4.65 6.09
Research & Development Expense		 6.59 11 13 20 14 27 27 23 45 59 25
Total Other Income / (Expense), net		 1.28 1.17 2.08 2.97 2.77 2.47 1.91 1.61 1.79 -5.30 0.00
Other Gains / (Losses), net		 - - - - - - - - - - 1.50
Basic Earnings per Share		 ($0.21) ($0.29) ($0.27) ($0.34) ($0.24) ($0.47) ($0.46) ($0.41) ($0.61) ($1.98) ($3.45)
Weighted Average Basic Shares Outstanding		 43.90M 43.90M 53.55M 63.80M 63.81M 61.26M 63.96M 64.03M 78.32M 73.20M 90.26M
Diluted Earnings per Share		 ($0.21) ($0.29) ($0.27) ($0.34) ($0.24) ($0.47) ($0.46) ($0.41) ($0.61) ($1.98) ($3.45)
Weighted Average Diluted Shares Outstanding		 43.90M 43.90M 53.55M 63.80M 63.81M 61.26M 63.96M 64.03M 78.32M 73.20M 90.26M
Weighted Average Basic & Diluted Shares Outstanding		 43.91M 63.80M 63.80M 63.81M 63.81M 64.03M 64.03M 85.59M 85.59M 103.88M 103.88M

Annual Cash Flow Statements for Larimar Therapeutics

This table details how cash moves in and out of Larimar Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -23 -3.24 8.43 8.55 -3.39 68 1.95 -43 -0.08 5.74 52
Net Cash From Operating Activities		 -60 -52 -44 -51 -23 -42 -42 -28 -33 -71 -113
Net Cash From Continuing Operating Activities		 -60 -52 -44 -51 -23 -42 -42 -28 -33 -71 -113
Net Income / (Loss) Continuing Operations		 -74 -58 -52 -61 -23 -42 -51 -35 -37 -81 -166
Consolidated Net Income / (Loss)		 -74 -58 -52 -61 -23 -42 -51 -35 -37 -81 -166
Depreciation Expense		 0.07 0.21 0.19 0.26 0.08 0.16 0.33 0.32 0.31 0.32 0.35
Amortization Expense		 1.24 1.04 0.25 -0.67 0.00 0.01 -0.01 -0.77 -1.84 -5.26 -1.70
Non-Cash Adjustments To Reconcile Net Income		 6.69 10 7.91 9.70 0.13 2.16 5.49 6.57 7.53 8.61 6.72
Changes in Operating Assets and Liabilities, net		 6.73 -5.50 -0.10 0.59 0.23 -2.04 2.73 1.67 -2.51 6.18 47
Net Cash From Investing Activities		 -92 51 36 -6.87 -0.08 17 24 -91 33 -85 100
Net Cash From Continuing Investing Activities		 -92 51 36 -6.87 -0.08 17 24 -91 33 -85 100
Purchase of Property, Plant & Equipment		 -0.60 -0.66 -0.06 -0.11 -0.08 -0.06 -0.33 -0.10 -0.16 -0.52 -0.09
Purchase of Investments		 -287 -137 -115 -117 0.00 -24 -8.25 -134 -101 -228 -84
Sale and/or Maturity of Investments		 196 189 150 110 0.00 1.00 33 43 135 143 184
Net Cash From Financing Activities		 129 -2.72 17 67 19 94 20 75 0.03 162 65
Net Cash From Continuing Financing Activities		 129 -2.72 17 67 19 94 20 75 0.03 162 65
Issuance of Common Equity		 131 0.22 0.20 67 0.00 76 20 75 0.00 162 65
Other Financing Activities, net		 - - - - 19 18 - 0.00 0.03 0.08 0.00

Quarterly Cash Flow Statements for Larimar Therapeutics

This table details how cash moves in and out of Larimar Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -56 -12 83 -78 2.76 -2.58 -12 -0.54 70 -4.73 93
Net Cash From Operating Activities		 -9.20 -9.34 -10 -14 24 -22 -27 -19 46 -113 -45
Net Cash From Continuing Operating Activities		 -9.20 -9.34 -10 -14 -25 -22 -27 -19 -29 -39 -45
Net Income / (Loss) Continuing Operations		 -9.06 -13 -15 -22 -15 -29 -29 -26 -48 -62 -30
Consolidated Net Income / (Loss)		 -9.06 -13 -15 -22 -15 -29 -29 -26 -48 -62 -30
Depreciation Expense		 0.08 0.08 0.08 0.09 0.07 0.08 0.09 0.09 0.09 0.09 0.06
Amortization Expense		 -0.57 -0.63 -0.58 -1.78 -1.71 -1.18 -0.76 -0.46 -0.33 -0.16 -0.08
Non-Cash Adjustments To Reconcile Net Income		 1.81 1.89 2.09 2.26 1.91 2.35 1.77 1.76 1.72 1.48 1.89
Changes in Operating Assets and Liabilities, net		 -1.46 2.31 2.66 7.07 -9.32 5.76 1.63 5.42 17 23 -17
Net Cash From Investing Activities		 -46 -2.63 -68 -63 132 19 14 19 -33 100 29
Net Cash From Continuing Investing Activities		 -46 -2.63 -68 -63 27 19 14 19 33 34 29
Purchase of Property, Plant & Equipment		 - -0.16 0.00 -0.27 -0.06 -0.18 -0.05 -0.02 -0.02 - 0.00
Purchase of Investments		 -56 -35 -85 -82 -23 -39 -53 -28 -3.46 - 0.00
Sale and/or Maturity of Investments		 9.99 33 17 19 50 58 67 47 37 34 29
Net Cash From Financing Activities		 0.03 - 162 -0.33 -162 0.04 0.00 - - 65 108
Net Cash From Continuing Financing Activities		 0.03 - 162 -0.33 0.03 0.04 0.00 - 65 -0.20 108
Issuance of Common Equity		 - - 162 -0.35 - - 0.00 - 65 -0.20 108
Other Financing Activities, net		 0.03 - - - 0.03 0.04 0.00 - - - 0.01

Annual Balance Sheets for Larimar Therapeutics

This table presents Larimar Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 189 132 106 122 5.20 105 79 126 96 200 146
Total Current Assets		 188 131 105 121 4.75 98 72 121 90 195 142
Cash & Equivalents		 36 32 41 49 1.01 68 70 27 27 33 85
Short-Term Investments		 149 97 61 69 0.00 24 0.00 92 60 150 51
Prepaid Expenses		 1.71 1.36 1.93 1.73 3.74 5.31 2.11 2.31 3.39 12 5.17
Plant, Property, & Equipment, net		 0.90 0.66 0.53 0.38 0.27 1.04 1.05 0.83 0.68 0.88 0.62
Total Noncurrent Assets		 0.09 0.06 0.06 0.06 0.18 5.69 5.41 4.84 5.08 4.04 3.20
Other Noncurrent Operating Assets		 0.09 0.06 0.06 0.06 0.18 5.69 5.41 4.84 5.08 4.04 3.20
Total Liabilities & Shareholders' Equity		 189 132 106 122 5.20 105 79 126 96 200 146
Total Liabilities		 20 9.89 27 28 5.90 15 14 16 14 28 68
Total Current Liabilities		 17 9.89 7.29 13 5.90 8.99 8.85 11 9.51 24 65
Accounts Payable		 7.50 2.57 3.02 3.59 3.54 2.63 1.66 1.69 1.28 2.42 5.22
Accrued Expenses		 6.11 3.73 4.27 4.26 2.26 5.84 6.59 8.41 7.39 21 58
Other Current Liabilities		 - - - - 0.10 0.52 0.59 0.61 0.84 1.06 1.11
Total Noncurrent Liabilities		 3.45 0.00 20 15 0.00 6.00 5.41 4.80 4.71 4.06 2.96
Other Noncurrent Operating Liabilities		 - - - - 0.00 6.00 5.41 4.80 4.71 4.06 2.96
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 169 122 78 93 -0.69 90 64 111 82 172 78
Total Preferred & Common Equity		 169 122 78 93 -0.69 90 64 111 82 172 78
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 169 122 78 93 -0.69 90 64 111 82 172 78
Common Stock		 349 359 368 444 22 155 181 263 270 441 513
Retained Earnings		 -180 -238 -290 -351 -23 -66 -116 -152 -189 -269 -435
Accumulated Other Comprehensive Income / (Loss)		 -0.21 -0.08 -0.06 -0.03 0.00 0.00 0.00 -0.03 0.08 0.15 0.05

Quarterly Balance Sheets for Larimar Therapeutics

This table presents Larimar Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 104 248 237 219 170 150 187 209
Total Current Assets		 98 231 231 213 165 146 183 205
Cash & Equivalents		 39 110 32 35 21 21 90 178
Short-Term Investments		 57 117 194 169 136 118 85 22
Prepaid Expenses		 2.89 3.66 5.07 9.55 7.96 7.03 7.79 4.59
Plant, Property, & Equipment, net		 0.60 0.60 0.84 0.78 0.86 0.80 0.71 0.56
Total Noncurrent Assets		 4.87 17 5.19 4.99 3.84 3.64 3.42 2.98
Other Noncurrent Operating Assets		 4.87 4.94 5.19 4.99 3.84 3.64 3.42 2.98
Total Liabilities & Shareholders' Equity		 104 248 237 219 170 150 187 209
Total Liabilities		 11 17 26 21 26 30 48 50
Total Current Liabilities		 6.56 13 21 16 22 27 45 48
Accounts Payable		 0.76 1.92 2.92 1.69 2.27 4.17 11 8.58
Accrued Expenses		 5.09 10 17 14 19 21 33 38
Other Current Liabilities		 0.71 0.83 0.99 1.03 1.10 1.13 1.15 1.06
Total Noncurrent Liabilities		 4.68 4.52 4.60 4.34 3.77 3.49 3.20 2.72
Other Noncurrent Operating Liabilities		 4.68 4.52 4.60 4.34 3.77 3.49 3.20 2.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 93 231 211 198 144 120 139 158
Total Preferred & Common Equity		 93 231 211 198 144 120 139 158
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 93 231 211 198 144 120 139 158
Common Stock		 268 434 436 438 443 444 511 622
Retained Earnings		 -176 -203 -225 -240 -298 -325 -372 -464
Accumulated Other Comprehensive Income / (Loss)		 0.01 -0.03 -0.15 0.36 0.05 -0.01 0.07 0.01

Annual Metrics And Ratios for Larimar Therapeutics

This table displays calculated financial ratios and metrics derived from Larimar Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 27,234,542.00 27,332,551.00 27,489,457.00 36,870,780.00 37,374,118.00 15,356,206.00 17,710,450.00 43,269,200.00 43,905,903.00 - 85,590,392.00
DEI Adjusted Shares Outstanding		 2,269,544.00 2,277,712.00 2,290,787.00 3,072,564.00 3,114,509.00 15,356,206.00 17,710,450.00 43,269,200.00 43,905,903.00 - 85,590,392.00
DEI Earnings Per Adjusted Shares Outstanding		 -32.73 -25.41 -22.71 -19.97 -7.43 -2.77 -2.86 -0.82 -0.84 - -1.94
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -104.27% 21.50% 8.02% -17.82% 62.68% -83.56% -18.92% 28.84% -7.46% -122.30% -103.23%
EBIT Growth		 -107.43% 21.21% 9.24% -16.08% 62.30% -83.65% -19.19% 30.18% -4.51% -118.15% -114.01%
NOPAT Growth		 -107.74% 21.12% 8.98% -15.33% 62.02% -84.39% -17.90% 27.62% -14.32% -117.66% -89.79%
Net Income Growth		 -103.65% 22.09% 10.11% -17.95% 62.31% -83.65% -19.19% 30.18% -4.51% -118.15% -105.54%
EPS Growth		 7.33% 23.74% 10.38% 0.00% 62.31% 6.05% 17.37% 53.56% 38.69% -57.14% -162.12%
Operating Cash Flow Growth		 -110.88% 12.73% 15.76% -17.59% 55.91% -85.91% 0.22% 34.52% -21.36% -111.48% -59.98%
Free Cash Flow Firm Growth		 -109.88% -1.99% 20.05% -14.33% 55.96% -53.57% -13.47% 27.19% -33.54% -80.05% -29.05%
Invested Capital Growth		 -176.64% 59.52% 1.11% -8.34% 59.01% -72.99% -92.94% -32.39% 32.62% -129.63% -404.78%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -18.17% 17.75% -5.74% -2.94% 43.10% -63.53% 9.33% -2.57% 2.94% -23.69% -29.37%
EBIT Q/Q Growth		 -20.24% 17.80% -5.51% -2.36% 42.60% -63.31% 9.21% -0.52% 2.86% -24.44% -30.68%
NOPAT Q/Q Growth		 -20.55% 17.99% -5.75% -2.23% 42.40% -64.55% 9.52% -3.85% -9.79% -23.23% -23.41%
Net Income Q/Q Growth		 -19.73% 18.03% -5.36% -2.48% 42.19% -63.61% 9.10% -0.83% -10.69% -24.44% -25.51%
EPS Q/Q Growth		 -157.08% 18.46% -5.56% -15.85% 42.19% -120.37% 3.28% 13.29% -42.37% -15.79% -77.44%
Operating Cash Flow Q/Q Growth		 -11.68% 15.15% -2.75% -4.04% 14.74% -4.83% 4.40% 4.32% -8.68% -21.40% -59.98%
Free Cash Flow Firm Q/Q Growth		 0.00% 11.92% -1.58% -3.27% 30.57% -23.64% 0.51% 3.32% -6.39% -15.95% -10.30%
Invested Capital Q/Q Growth		 -32.80% 6.89% -42.99% -21.67% 63.67% -987.35% 4.58% -24.65% -76.16% -119.37% -61.46%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 96.04%
Interest Burden Percent		 100.50% 99.37% 98.43% 100.01% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -54.31% -39.80% -52.04% -71.57% -49.97% -95.47% -65.72% -40.33% -38.36% -63.58% -132.59%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -54.31% -39.80% -52.04% -71.57% -49.97% -95.47% -65.72% -40.33% -38.36% -63.58% -132.59%
Return on Equity Simple (ROE_SIMPLE)		 -43.93% -47.55% -66.52% -65.80% 3,333.14% -47.36% -78.61% -31.88% -45.21% -46.91% 0.00%
Net Operating Profit after Tax (NOPAT)		 -52 -41 -37 -43 -16 -30 -35 -26 -29 -64 -121
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15.78% -11.25% -14.38% -20.71% -13.98% -26.74% -18.82% -10.38% -7.52% -12.57% -28.05%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -35.77% -37.03% -154.64%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -74 -58 -53 -61 -23 -42 -51 -35 -37 -81 -172
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -73 -57 -52 -62 -23 -42 -50 -36 -38 -86 -174
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.01 0.71 1.62 1.96 0.00 3.67 2.97 1.61 2.44 1.44 4.18
Price to Tangible Book Value (P/TBV)		 1.01 0.71 1.62 1.96 0.00 3.67 2.97 1.61 2.44 1.44 4.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.04 0.03 0.26 0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.02 0.00 0.26 0.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.05 -1.05 -1.04 -1.05 -1.06 -1.05 -1.06 -1.08 -1.07 -1.07 -1.28
Leverage Ratio		 1.12 1.10 1.19 1.33 1.37 1.23 1.19 1.17 1.15 1.17 1.38
Compound Leverage Factor		 1.13 1.10 1.17 1.33 1.37 1.23 1.19 1.17 1.15 1.17 1.38
Debt to Total Capital		 3.64% 2.86% 20.36% 18.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 1.67% 2.86% 0.00% 4.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.97% 0.00% 20.36% 13.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 96.36% 97.14% 79.64% 81.88% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.09 -0.06 -0.38 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 2.46 2.20 1.57 1.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.05 0.00 -0.38 -0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.12 -0.09 -0.54 -0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 3.46 3.08 2.21 2.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.07 0.00 -0.54 -0.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.61 2.39 -1.59 -0.79 -16.95 11.96 4.82 5.36 5.42 3.03 -4.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 11.37 13.23 14.39 9.12 0.81 10.89 8.16 11.28 9.49 8.02 2.19
Quick Ratio		 11.19 13.06 13.99 8.87 0.17 10.30 7.92 11.06 9.13 7.53 2.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -46 -46 -37 -42 -19 -29 -33 -24 -32 -57 -74
Operating Cash Flow to CapEx		 -10,009.08% -7,875.00% -79,607.27% -47,673.15% -27,348.19% -68,062.90% -12,644.14% -27,569.00% -20,401.83% -13,739.81% -124,396.70%
Free Cash Flow to Firm to Interest Expense		 -56.52 -87.83 -225.10 -22.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -73.89 -98.25 -265.36 -27.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -74.63 -99.50 -265.69 -27.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.58 -3.88 -3.84 -4.16 -1.70 -2.95 -5.68 -7.53 -5.07 -12 -59
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -6.12 5.70 0.04 -0.32 2.45 -1.24 -2.74 -1.84 2.46 -6.57 -47
Enterprise Value (EV)		 -7.38 -39 45 85 40 236 121 60 113 63 189
Market Capitalization		 171 87 127 183 41 329 191 179 200 247 326
Book Value per Share		 $6.21 $4.45 $2.85 $2.53 ($0.02) $5.84 $3.64 $2.56 $1.86 $2.69 $0.91
Tangible Book Value per Share		 $6.21 $4.45 $2.85 $2.53 ($0.02) $5.84 $3.64 $2.56 $1.86 $2.69 $0.91
Total Capital		 175 125 98 114 -0.69 90 64 111 82 172 78
Total Debt		 6.39 3.59 20 21 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 3.45 0.00 20 15 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -179 -126 -82 -97 -1.01 -93 -70 -118 -87 -183 -137
Capital Expenditures (CapEx)		 0.60 0.66 0.06 0.11 0.08 0.06 0.33 0.10 0.16 0.52 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -4.60 -4.42 -4.59 -2.15 -3.68 -6.74 -8.39 -6.12 -13 -60
Debt-free Net Working Capital (DFNWC)		 175 125 98 113 -1.15 89 63 110 81 171 77
Net Working Capital (NWC)		 172 121 98 108 -1.15 89 63 110 81 171 77
Net Nonoperating Expense (NNE)		 23 17 15 19 6.88 13 15 9.79 7.72 17 45
Net Nonoperating Obligations (NNO)		 -179 -126 -82 -97 -1.01 -93 -70 -118 -87 -183 -137
Total Depreciation and Amortization (D&A)		 1.31 1.25 0.43 -0.41 0.08 0.17 0.31 -0.46 -1.53 -4.94 -1.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($33.36) ($25.44) ($22.80) ($22.80) ($14.64) ($3.57) ($2.95) ($1.37) ($0.84) ($1.32) ($3.46)
Adjusted Weighted Average Basic Shares Outstanding		 2.27M 2.28M 2.30M 3.11M 3.12M 15.37M 17.16M 25.76M 43.90M 61.26M 73.20M
Adjusted Diluted Earnings per Share		 ($33.36) ($25.44) ($22.80) ($22.80) ($14.64) ($3.57) ($2.95) ($1.37) ($0.84) ($1.32) ($3.46)
Adjusted Weighted Average Diluted Shares Outstanding		 2.27M 2.28M 2.30M 3.11M 3.12M 15.37M 17.16M 25.76M 43.90M 61.26M 73.20M
Adjusted Basic & Diluted Earnings per Share		 ($33.36) ($25.44) ($22.80) ($22.80) ($14.64) ($3.57) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.23M 2.27M 2.29M 2.69M 3.11M 11.88M 17.71M 43.27M 63.80M 64.03M 103.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -52 -41 -37 -43 -16 -30 -35 -26 -29 -64 -121
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -91.71 -110.10 -320.36 -32.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -64.11 -77.05 -224.84 -22.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -92.45 -111.35 -320.69 -32.39 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -64.84 -78.29 -225.18 -22.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.64% 0.00% 0.00% -0.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Larimar Therapeutics

This table displays calculated financial ratios and metrics derived from Larimar Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 43,277,500.00 43,905,903.00 63,800,017.00 63,802,017.00 63,806,628.00 - 64,027,892.00 64,027,892.00 85,590,392.00 85,590,392.00 103,882,937.00
DEI Adjusted Shares Outstanding		 43,277,500.00 43,905,903.00 63,800,017.00 63,802,017.00 63,806,628.00 - 64,027,892.00 64,027,892.00 85,590,392.00 85,590,392.00 103,882,937.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.21 -0.30 -0.23 -0.34 -0.24 - -0.46 -0.41 -0.56 -0.73 -0.29
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -12.40% -22.37% -114.57% -180.30% -79.40% -120.96% -97.59% -13.89% -179.78% -114.13% -3.96%
EBIT Growth		 -6.47% -24.47% -124.55% -158.51% -71.00% -121.84% -99.82% -21.06% -207.84% -122.10% -6.27%
NOPAT Growth		 -21.45% -35.66% -119.12% -155.71% -76.65% -120.96% -86.38% -12.98% -171.02% -104.58% 0.23%
Net Income Growth		 -8.94% -37.86% -124.55% -158.51% -71.00% -121.84% -99.82% -21.06% -207.84% -116.83% -1.13%
EPS Growth		 43.24% -625.00% -80.00% -78.95% -14.29% -62.07% -70.37% -20.59% -154.17% -321.28% -650.00%
Operating Cash Flow Growth		 -56.52% -40.03% -37.88% -89.93% 365.21% -133.49% -154.92% -38.55% 88.21% -59.98% -68.10%
Free Cash Flow Firm Growth		 -76.83% -126.27% -59.98% 6.86% 0.39% -23.97% -89.49% -126.15% 65.63% 115.08% 143.70%
Invested Capital Growth		 52.33% 32.62% -54.51% -243.33% -84.40% -129.63% -62.38% -27.35% -585.83% -404.78% -219.52%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -14.83% -41.79% -11.90% -53.84% 26.50% -74.64% -0.06% 11.33% -80.56% -33.66% 51.42%
EBIT Q/Q Growth		 -8.34% -43.35% -12.78% -47.58% 28.34% -85.97% -1.59% 10.58% -82.23% -34.18% 51.39%
NOPAT Q/Q Growth		 -7.47% -36.98% -18.16% -47.00% 25.75% -71.34% 0.34% 10.89% -78.11% -29.33% 51.39%
Net Income Q/Q Growth		 -8.34% -43.35% -12.78% -47.58% 28.34% -85.97% -1.59% 10.58% -82.23% -30.99% 52.62%
EPS Q/Q Growth		 -10.53% -38.10% 6.90% -25.93% 29.41% -95.83% 2.13% 10.87% -48.78% -224.59% -74.24%
Operating Cash Flow Q/Q Growth		 -24.92% -1.55% -11.43% -34.36% 274.43% 11.13% 62.49% 26.97% 336.94% -346.51% 60.59%
Free Cash Flow Firm Q/Q Growth		 -41.79% -18.97% 28.58% 22.69% -51.64% -48.06% -9.17% 7.74% 76.95% 164.97% 216.34%
Invested Capital Q/Q Growth		 32.60% -76.16% -61.01% -79.59% 63.80% -119.37% -13.86% -40.85% -94.95% -61.46% 27.93%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 90.16% 95.17%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 108.29% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.58% -38.36% -26.75% -37.48% -44.50% -63.58% -50.77% -60.25% -78.24% -132.59% -109.83%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -31.58% -38.36% -26.75% -37.48% -44.50% -63.58% -50.77% -60.25% -78.24% -132.59% -109.83%
Return on Equity Simple (ROE_SIMPLE)		 -36.01% 0.00% -19.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.24 -9.91 -12 -17 -13 -22 -22 -19 -35 -45 -22
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.66% -3.00% -1.68% -2.67% -1.81% -5.12% -3.76% -3.69% -6.89% -11.04% -4.38%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.13% -5.07% -8.15% -6.44% -12.75% -15.13% -16.23% -24.92% -57.39% -13.78%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.06 -13 -15 -22 -15 -29 -29 -26 -48 -64 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.55 -14 -15 -23 -17 -30 -30 -27 -48 -64 -31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.84 2.44 2.10 2.19 2.11 1.44 0.95 1.54 1.99 4.18 2.96
Price to Tangible Book Value (P/TBV)		 1.84 2.44 2.10 2.19 2.11 1.44 0.95 1.54 1.99 4.18 2.96
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.07 -1.04 -1.06 -1.03 -1.07 -1.06 -1.10 -1.12 -1.28 -1.18
Leverage Ratio		 1.12 1.15 1.09 1.12 1.11 1.17 1.12 1.17 1.20 1.38 1.25
Compound Leverage Factor		 1.12 1.15 1.09 1.12 1.11 1.17 1.12 1.17 1.20 1.50 1.25
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.53 6.24 16.45 10.21 11.47 3.88 1.18 1.03 0.70 -2.10 2.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.02 9.49 17.99 10.93 13.10 8.02 7.48 5.46 4.06 2.19 4.29
Quick Ratio		 14.58 9.13 17.70 10.69 12.51 7.53 7.12 5.20 3.89 2.11 4.20
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -10 -12 -8.83 -6.83 -10 -15 -17 -15 -3.56 2.31 7.32
Operating Cash Flow to CapEx		 0.00% -5,696.95% 0.00% -5,105.11% 39,353.23% -12,187.15% -54,163.27% -102,005.26% 199,656.52% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.88 -5.07 -8.16 -15 -5.31 -12 -13 -19 -36 -59 -42
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.16 2.46 -2.88 -10 -2.43 -6.57 -5.09 -4.01 -31 -47 -29
Enterprise Value (EV)		 75 113 245 237 214 63 -20 47 101 189 267
Market Capitalization		 171 200 484 463 418 247 138 185 276 326 467
Book Value per Share		 $2.14 $1.86 $3.62 $3.31 $3.11 $2.69 $2.25 $1.87 $1.62 $0.91 $1.52
Tangible Book Value per Share		 $2.14 $1.86 $3.62 $3.31 $3.11 $2.69 $2.25 $1.87 $1.62 $0.91 $1.52
Total Capital		 93 82 231 211 198 172 144 120 139 78 158
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -96 -87 -239 -226 -204 -183 -158 -139 -175 -137 -200
Capital Expenditures (CapEx)		 0.00 0.16 0.00 0.27 0.06 0.18 0.05 0.02 0.02 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.67 -6.12 -9.18 -16 -6.74 -13 -14 -20 -37 -60 -43
Debt-free Net Working Capital (DFNWC)		 92 81 218 210 197 171 143 119 138 77 157
Net Working Capital (NWC)		 92 81 218 210 197 171 143 119 138 77 157
Net Nonoperating Expense (NNE)		 1.83 3.08 2.94 4.41 2.71 6.92 7.45 6.73 13 18 7.83
Net Nonoperating Obligations (NNO)		 -96 -87 -239 -226 -204 -183 -158 -139 -175 -137 -200
Total Depreciation and Amortization (D&A)		 -0.49 -0.55 -0.50 -1.69 -1.64 -1.11 -0.67 -0.37 -0.24 -0.07 -0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.21) ($0.29) ($0.27) ($0.34) ($0.24) ($0.47) ($0.46) ($0.41) ($0.61) ($1.98) ($3.45)
Adjusted Weighted Average Basic Shares Outstanding		 43.90M 43.90M 53.55M 63.80M 63.81M 61.26M 63.96M 64.03M 78.32M 73.20M 90.26M
Adjusted Diluted Earnings per Share		 ($0.21) ($0.29) ($0.27) ($0.34) ($0.24) ($0.47) ($0.46) ($0.41) ($0.61) ($1.98) ($3.45)
Adjusted Weighted Average Diluted Shares Outstanding		 43.90M 43.90M 53.55M 63.80M 63.81M 61.26M 63.96M 64.03M 78.32M 73.20M 90.26M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.91M 63.80M 63.80M 63.81M 63.81M 64.03M 64.03M 85.59M 85.59M 103.88M 103.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.24 -9.91 -12 -17 -13 -22 -22 -19 -35 -45 -22
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Larimar Therapeutics (NASDAQ: LRMR) continues to look like a clinical-stage biotech with a strong cash position, but also one that is still burning cash at a meaningful rate. The latest quarter shows no revenue, continued operating losses, and heavy reliance on financing and investment income to support operations.

  • Cash and short-term investments totaled about $200.4 million at March 31, 2026, giving the company a sizeable liquidity cushion.
  • Total current assets of $205.0 million far exceeded total current liabilities of $47.8 million, suggesting near-term balance sheet flexibility.
  • The company raised significant capital in Q1 2026, including $108.1 million from common equity issuance, which helped offset operating losses and build cash.
  • Q1 2026 net cash from financing activities was $108.1 million, more than covering the quarter’s operating cash burn.
  • The company also benefited from $29.0 million in investing cash inflows, mainly from sales/maturities of investments.
  • Compared with Q1 2025, total assets rose from $170.2 million to $208.5 million, reflecting a stronger liquidity position.
  • Larimar remains pre-revenue, with $0 in revenue in every quarter shown.
  • The business is still heavily R&D driven, with Q1 2026 research and development expense at $25.0 million.
  • Operating expenses in Q1 2026 were $31.1 million, down from $64.0 million in Q4 2025, but still substantial for a company without sales.
  • Shares outstanding have increased over time, with Q1 2026 basic weighted average shares at about 90.3 million versus 63.9 million in Q1 2025, indicating dilution from equity financing.
  • Larimar reported a Q1 2026 net loss of $29.6 million, or -$3.45 per share.
  • Operating cash flow was a negative $44.6 million in Q1 2026, showing the company is still consuming cash to fund its pipeline.
  • Q1 2026 cash and equivalents fell sharply from $90.1 million in Q3 2025 to $17.8 million, with the drop offset by large short-term investments and financing activity.
  • Retained earnings remained deeply negative at -$464.4 million in Q1 2026, underscoring the cumulative losses the company has incurred.
  • The latest quarter’s liquidity improvement came partly from equity issuance, which can be a red flag for existing shareholders because it can dilute ownership.

Overall, LRMR appears well-capitalized for the near term, but the long-term investment case still depends on clinical progress and eventual commercialization. For now, the financial story is less about profitability and more about how long the company can fund development before needing additional capital.

07/04/26 01:31 PM ETAI Generated. May Contain Errors.

Larimar Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Larimar Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Larimar Therapeutics' net income appears to be on an upward trend, with a most recent value of -$165.67 million in 2025, rising from -$74.29 million in 2015. The previous period was -$80.60 million in 2024. See Larimar Therapeutics' forecast for analyst expectations on what's next for the company.

Larimar Therapeutics' total operating income in 2025 was -$172.50 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $172.50 million

Over the last 10 years, Larimar Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Larimar Therapeutics' total liabilities were at $67.76 million at the end of 2025, a 138.5% increase from 2024, and a 238.9% increase since 2015.

In the past 10 years, Larimar Therapeutics' cash and equivalents has ranged from $1.01 million in 2019 to $85.41 million in 2025, and is currently $85.41 million as of their latest financial filing in 2025.

Over the last 10 years, Larimar Therapeutics' book value per share changed from 6.21 in 2015 to 0.91 in 2025, a change of -85.3%.


Related Companies

Financial statements for NASDAQ:LRMR last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel
He turned $12,415 into millions. Now he wants to help you.
Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...
Tim Sykes | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Gold to $4,900—Here’s the Real Play
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
The startup growing 23 times faster than Nvidia
An official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...
Brownstone Research | Sponsoredtc pixel
Are we ignoring the same signal Wall Street ignored in 1929?
In 1929, a 20-something broker named Irving Weiss shorted the market before Black Monday and made a fortune. H...
Weiss Ratings | Sponsoredtc pixel